港股异动 | 友邦(1299.HK)高开2.59% 友邦人寿获批开始筹建四川分公司
格隆汇11月3日丨友邦(1299.HK)高开2.59%,报75.25港元,总市值9100亿港元。2020年11月2日,友邦保险集团宣布友邦人寿保险有限公司(友邦人寿)已获得中国银行保险监督管理委员会(中国银保监会)批准,开始筹建四川分公司。这将是友邦于今年在中国内地成功设立独资人身保险子公司后获批筹建的首家分公司。随着四川分公司的获批筹建,友邦人寿的展业范围增至8个国内市场:上海、北京、江苏、广东、深圳、天津、石家庄和四川。据了解,友邦人寿下一批考虑布点的地区,或集中在山东、河南等地,这些省份的共同特点是:常住人口较多、经济发展崛起、民众保险意识较强。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.